(# co-first author, * correspondence)

2025

• • Ding J#, Sun B#, Gao Y#, Gu C, Zhang J, Wang L, Zheng J*, Xia B*, Qi X*. APOE4 Exacerbates Cerebral Tau Pathology Through Cholesterol-Induced Degradation of Phosphatase in Atherosclerosis. CNS Neurosci Ther. 2025;31(8):e70536

2024

• • Qi X#, Yuan S#, Ding J#, Sun W, Shi Y, Xing Y, Liu Z, Yao Y, Fu S, Sun B, Qi X, Xia B, Liu F, Yi M, Mao J, Wan Y*, Zheng J*. Emerging signs of Alzheimer-like tau hyperphosphorylation and neuroinflammation in the brain post recovery from COVID-19. Aging Cell. 2024. 23(11):e14352

  • Su J#, Xiao Y#, Wang X, Zheng J*, Wang JZ*. Development of tau phosphorylation-targeting therapies for the treatment of neurodegenerative diseases. Medicine Plus. 2024. 1(4):10060. Review

• Xiao Y#, Wei L#, Su J#, Lei H, Sun F, Li M, Li S, Wang X*, Zheng J*, Wang JZ*. A tau dephosphorylation-targeting chimera selectively recruits protein phosphatase-1 to ameliorate Alzheimer's disease and tauopathies. Cell Chem Biol. 2024. 31(10):1787-1799.e6. | News in AlzForum

• Su J#, Xiao Y#, Wei L, Lei H, Sun F, Wang W, Li S, Wang X*, Zheng J*, Wang JZ*. A new tau dephosphorylation-targeting chimera for the treatment of tauopathies. Acta Pharmacol Sin. 2024. 45(11):2267-2276

• Su J#, Xiao Y#, Wei L, Lei H, Sun F, Wang W, Yin J, Xiong R, Li S, Zhang P, Zhou Y, Wang X*, Zheng J*, Wang JZ*. Generation of tau dephosphorylation-targeting chimeras for the treatment of Alzheimer's disease and related tauopathies. Sci Bull. 2024. 69(8):1137-1152. | News in Science China Press, Healthmedicinet

2023

• • Shi Y, Wan Y, Zheng J*. Waking up neural stem cells through inhibition of mitochondrial pyruvate import. Brain‐X. 2023. 1(2).e13. Commentary

  • Gao Y#*, Wang YY#, Lei HY, Xu ZD, Li SH, Yu HT, Xie JZ, Zhang ZT, Liu GP, Zhang Y*, Zheng J*, Wang JZ*. A novel transgenic mouse line with hippocampus-dominant and inducible expression of truncated human tau. Transl Neurodegener. 2023. 12(1), 51. 

  • Gao Y#, Yu H#, Liu Y, Xu Z, He B, Liu H, Wang Y, Zhang Y, Liang Y, Yang Y, Zheng J*, Wang JZ*. GSK-3β activation mediates apolipoprotein E4-associated cognitive impairment in type 2 diabetes mellitus: A multicenter, cross-sectional study. J Diabetes. 2023. 16(1):e13470.

• 2022

• Zheng J. Hippocampal neurogenesis and pro-neurogenic therapies for Alzheimer's disease. Animal Model Exp Med. 2022. 5(1):3-14. Review (Cover story)  

2021

• Zheng J#*, Tian N#, Liu F, Zhang Y, Su J, Gao Y, Deng M, Wei L, Ye J, Li H, Wang JZ*. A novel dephosphorylation targeting chimera selectively promoting tau removal in tauopathies. Signal Transduct Target Ther. 2021. 6(1):269. (Cover story) | 设计了一种能靶向诱导tau蛋白去磷酸化的多肽嵌合体DEPTAC，在细胞和小鼠模型上进行了效果测试。| Comment: Curr Protein Pept Sci

• Zheng J*, Li Y. Compensation for Neurodegeneration by Hippocampal Neurogenesis in Alzheimer's Disease: Where is the Way? Neurosci Bull. 2021. 37(6):885-888. Insight

2020

• Zheng J#*, Li HL#, Tian N, Liu F, Wang L, Yin YL, Yue LP, Ma LY, Wan Y, Wang JZ*. Interneuron accumulation of phosphorylated tau impairs adult hippocampal neurogenesis by suppressing GABAergic transmission. Cell Stem Cell. 2020. 26(3):331-345.e6. | 发现AD脑内海马齿状回磷酸化tau大量聚集于GABA能中间神经元胞内，引起局部神经网络去抑制，导致神经干细胞源性星形胶质增生增加、神经元新生减少。| Highlight:  Cell Stem Cell

• Liu F, Tian Na, Zhang HQ, Li SH, Zhou QZ, Zheng J*, Wang JZ*. GSK-3β activation accelerates early-stage consumption of hippocampal neurogenesis in senescent mice. Theranostics. 2020. 10(21):9674-9685.

2016/2017

• Zheng J, Jiang YY, Ma LY, Liu FY, Cui S, Cai J, Liao FF, Wan Y*, Yi M*. Adult hippocampal neurogenesis along the dorsoventral axis contributes differentially to environmental enrichment combined with voluntary exercise in alleviating chronic inflammatory pain in mice. J Neurosci. 2017. 37(15):4145-4157.

• Zheng J, Yi M, Wan Y*.  Hippocampal neurogenesis: does it relieve or worsen chronic pain?  Pain. 2016. 157(2):506-507. Letter to editor